Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

C Kobe, M Dietlein, J Franklin, J Markova, A Lohri, H Amthauer, S Klutmann, WH Knapp, JM Zijlstra, A Bockisch, M Weckesser, R Lorenz, M Schreckenberger, R Bares, HT Eich, RP Mueller, M Fuchs, P Borchmann, H Schicha, V Diehl, A Engert

. 2008 ; 112 (10) : 3989-3994.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc14065745

Grantová podpora
NR8033 MZ0 CEP - Centrální evidence projektů

In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron emission tomography (PET) using [(18)F]-fluorodeoxyglucose in advanced-stage Hodgkin lymphoma (HL) was evaluated. A total of 817 patients were enrolled and randomly assigned to receive BEACOPP-based chemotherapy. After completion of chemotherapy, residual disease measuring more than or equal to 2.5 cm in diameter was assessed by PET in 311 patients. The NPV of PET was defined as the proportion of PET(-) patients without progression, relapse, or irradiation within 12 months after PET review panel. The progression-free survival was 96% for PET(-) patients (95% confidence interval [CI], 94%-99%) and 86% for PET(+) patients (95% CI, 78%-95%, P = .011). The NPV for PET in this analysis was 94% (95% CI, 91%-97%). Thus, consolidation radiotherapy can be omitted in PET(-) patients with residual disease without increasing the risk for progression or early relapse compared with patients in complete remission. The impact of this finding on the overall survival at 5 years must be awaited. Until then, response adapted therapy guided by PET for HL patients seems to be a promising approach that should be further evaluated in clinical trials. This trial is registered at http://isrctn.org study as #ISRCTN32443041.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc14065745
003      
CZ-PrNML
005      
20200521102605.0
007      
ta
008      
140718s2008 xxud f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2008-06-155820 $2 doi
035    __
$a (PubMed)18757777
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kobe, Carsten $u Department of Nuclear Medicine, University of Cologne, Cologne, Germany
245    10
$a Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma / $c C Kobe, M Dietlein, J Franklin, J Markova, A Lohri, H Amthauer, S Klutmann, WH Knapp, JM Zijlstra, A Bockisch, M Weckesser, R Lorenz, M Schreckenberger, R Bares, HT Eich, RP Mueller, M Fuchs, P Borchmann, H Schicha, V Diehl, A Engert
504    __
$a Literatura
520    9_
$a In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron emission tomography (PET) using [(18)F]-fluorodeoxyglucose in advanced-stage Hodgkin lymphoma (HL) was evaluated. A total of 817 patients were enrolled and randomly assigned to receive BEACOPP-based chemotherapy. After completion of chemotherapy, residual disease measuring more than or equal to 2.5 cm in diameter was assessed by PET in 311 patients. The NPV of PET was defined as the proportion of PET(-) patients without progression, relapse, or irradiation within 12 months after PET review panel. The progression-free survival was 96% for PET(-) patients (95% confidence interval [CI], 94%-99%) and 86% for PET(+) patients (95% CI, 78%-95%, P = .011). The NPV for PET in this analysis was 94% (95% CI, 91%-97%). Thus, consolidation radiotherapy can be omitted in PET(-) patients with residual disease without increasing the risk for progression or early relapse compared with patients in complete remission. The impact of this finding on the overall survival at 5 years must be awaited. Until then, response adapted therapy guided by PET for HL patients seems to be a promising approach that should be further evaluated in clinical trials. This trial is registered at http://isrctn.org study as #ISRCTN32443041.
590    __
$a bohemika - dle Pubmed
650    02
$a mladiství $7 D000293
650    02
$a dospělí $7 D000328
650    12
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    02
$a bleomycin $x aplikace a dávkování $7 D001761
650    02
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    02
$a přežití bez známek nemoci $7 D018572
650    02
$a doxorubicin $x aplikace a dávkování $7 D004317
650    02
$a etoposid $x aplikace a dávkování $7 D005047
650    12
$a fluorodeoxyglukosa F18 $x aplikace a dávkování $7 D019788
650    12
$a Hodgkinova nemoc $x farmakoterapie $x mortalita $x radiografie $7 D006689
650    02
$a lidé $7 D006801
650    02
$a mužské pohlaví $7 D008297
650    02
$a lidé středního věku $7 D008875
650    02
$a reziduální nádor $7 D018365
650    02
$a pozitronová emisní tomografie $x metody $7 D049268
650    12
$a pozitronová emisní tomografie $7 D049268
650    02
$a prediktivní hodnota testů $7 D011237
650    02
$a prednison $x aplikace a dávkování $7 D011241
650    02
$a prokarbazin $x aplikace a dávkování $7 D011344
650    12
$a radiofarmaka $x aplikace a dávkování $7 D019275
650    02
$a rizikové faktory $7 D012307
650    02
$a míra přežití $7 D015996
650    02
$a vinkristin $x aplikace a dávkování $7 D014750
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Dietlein, Markus $u Department of Nuclear Medicine, University of Cologne, Cologne, Germany
700    1_
$a Franklin, Jeremy $u German Hodgkin Study Group, University of Cologne, Cologne, Germany
700    1_
$a Marková, Jana $7 xx0143313 $u Department of Clinical Hematology, Tinird Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Lohri, Andreas $u Schweizer Arbeitsgruppe fúr Klinische ebsforschung, Bern, Switzerland
700    1_
$a Amthauer, Holger $u Klinik für Strahlenheilkunde, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany $7 gn_A_00005772
700    1_
$a Klutmann, Susanne $u Department Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Knapp, Wolfram H. $u Department of Nuclear Medicine, Hanover University Medical School, Hanover, Germany
700    1_
$a Zijlstra, Josee M. $u Department of Hematology, VU University Medical Centre, Amsterdam, The Netherlands
700    1_
$a Bockisch, Andreas $u Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany
700    1_
$a Weckesser, Matthias $u Department of Nuclear Medicine, Universilsity Hospital Muenster, Muenster, Germany
700    1_
$a Lorenz, Reinhard $u Department of Nuclear Medicine, University of Wuerzburg, Wuerzburg, Germany
700    1_
$a Schreckenberger, Mathias $u Department of Nuclear Medicine, Gutenberg University Hospital, Mainz, Germany
700    1_
$a Bares, Roland $u Department of Nuclear Medicine, University of Tuebingen, Tuebingen, Germany
700    1_
$a Eich, Hans T. $u Department of Radiation Oncology, University of Cologne, Cologne, Germany
700    1_
$a Mueller, Rolf-Peter $u Department of Radiation Oncology, University of Cologne, Cologne, Germany
700    1_
$a Fuchs, Michael $u German Hodgkin Study Group, University of Cologne, Cologne, Germany; Department of Internal Medicine, University of Cologne, Cologne, Germany
700    1_
$a Borchmann, Peter $u German Hodgkin Study Group, University of Cologne, Cologne, Germany; Department of Internal Medicine, University of Cologne, Cologne, Germany
700    1_
$a Schicha, Herald $u Department of Nuclear Medicine, University of Cologne, Cologne, Germany
700    1_
$a Diehl, Volker $u German Hodgkin Study Group, University of Cologne, Cologne, Germany
700    1_
$a Engert A $u German Hodgkin Study Group, University of Cologne, Cologne, Germany; Department of Internal Medicine, University of Cologne, Cologne, Germany
773    0_
$t Blood $g Roč. 112, č. 10 (2008), s. 3989-3994 $p Blood $x 0006-4971 $w MED00000807
773    0_
$p Blood $g 112(10):3989-94, 2008 Nov 15
910    __
$a ABA008 $b B 405 $c 315 $y 4 $z 0
990    __
$a 20140718084047 $b ABA008
991    __
$a 20200521102619 $b ABA008
999    __
$a ok $b bmc $g 1033213 $s 864520
BAS    __
$a 3
BMC    __
$a 2008 $b 112 $c 10 $d 3989-3994 $x MED00000807 $i 0006-4971 $m Blood $n Blood
GRA    __
$a NR8033 $p MZ0
LZP    __
$a 2014-07/gvbo

Najít záznam

Citační ukazatele

Možnosti archivace